The efficacy and safety of recombinant human granulocyte colony stimulating factor primed donor peripheral cell harvest in treatment of poor graft function after allogeneic stem cell transplantation
10.3760/cma.j.issn.0578-1426.2013.09.005
- VernacularTitle:重组人粒细胞集落刺激因子动员的供者外周血采集物治疗异基因造血干细胞移植后植入功能不良的疗效和安全性
- Author:
Yuqian SUN
;
Daihong LIU
;
Lanping XU
;
Xiaohui ZHANG
;
Kaiyan LIU
;
Xiaojun HUANG
- Publication Type:Journal Article
- Keywords:
Granulocyte colony stimulating factor,recombinant;
Hematopoietic stem cell transplantation,allogeneic;
Poor graft function
- From:
Chinese Journal of Internal Medicine
2013;52(9):730-733
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of recombinant human granulocyte colony stimulating factor (rhG-CSF) primed donor peripheral blood stem cell (PBSC) on the treatment of poor graft function (PGF) after allogeneic stem cell transplantation(allo-HSCT).Methods The patients diagnosed as PGF after allo-HSCT and transfused with rhG-CSF primed PBSC from January 2003 to November 2012 were retrospectively analyzed.Hematological response was assessed at day 30 after transfusion.Graft versus host disease (GVHD) was assessed until 6 months after transfusion.Results There were 28 patients including 21 men and 7 women with a median age of 28 (12-50) years old.Of these patients,16 were diagnosed as primary PGF.The median number of transfused mononuclear cells was 2.0 (1.0-5.8) ×108/kg.Totally 42.9％ (12/28) patients achieved good response.Eight patients (28.6％) developed GVHD.Sixteen patients (57.1％) survived.Age (≤/＞ 28 years),gender,donor type (matched sibling/mismatched related),additional conditioning regimen prior to transfusion,time of neutrophil engraftment (≤/＞ 18 days) time of transfusion (≤/＞ 100 days after allo-HSCT) and number of mononuclear cells (≤/＞ 2.0 × 108/kg) did not impact hematological response.However,response rate of primary PGF (4/16) was significantly lower than that of secondary PGF (8/12) (P =0.022).Conclusion Transfusion of PBSC mobilized by rhG-CSF could be considered as an option to treat secondary PGF after allogeneic stem cell transplantation.
